TORONTO, Dec. 19 /CNW/ - Amorfix Life Sciences Ltd., a company focused on diagnostics and treatments for brain wasting diseases, announced today that in addition to their own investment, the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) will share in the research and development of the company’s proposed diagnostic test for Alzheimer’s disease, EP-AD(TM), via a contribution of $322,000.
